Linking MSMEG_1353 to lipid metabolism and envelope integrity in Mycolicibacterium smegmatis

Mycobacterium tuberculosis (Mtb) poses a significant global health burden. Rv0647c, an essential Mtb cell wall protein, is a potential drug target. We studied its Mycolicibacterium smegmatis (MSMEG) homologue, MSMEG_1353, using a CRISPRi conditional knockdown. MSMEG_1353 depletion increased cell width and volume, delayed log-phase initiation, slowed aggregation, reduced biofilm formation, and heightened susceptibility to antibiotics and sodium dodecyl sulfate (SDS). AlphaFold, sequence alignment, and UNIPROT analyses suggest MSMEG_1353 functions as a protein kinase, with conserved residues in intermediate high-confidence regions potentially forming an ATP-binding site. Investigating its role in cell envelope biosynthesis, mass spectrometry revealed elevated levels of mycolic acid biosynthesis proteins upon MSMEG_1353 knockdown. RT-qPCR confirmed upregulation of the fabD-acpM-kasA-KasB-accD6 operon, encoding key mycolic acid synthesis enzymes. Notably, a strong negative correlation with MSMEG_0911, the predominant isocitrate lyase, important in the glyoxylate cycle, was observed via both MS and RT-qPCR. Collectively, MSMEG_1353 deficiency compromises cell wall integrity, likely due to altered lipid composition resulting from dysregulated mycolic acid biosynthesis and lipid metabolism. These findings support the development of models explaining MSMEG_1353's involvement in these pathways.